HARNESSING THE POWER OF
THE INNATE IMMUNE SYSTEM

INmune Bio, Inc. is focused on modulating components of the innate immune system to activate an immune response against cancer.
Subscribe to our newsletter
logoNew2

About Us
INmuneBio

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.

Learn more

Products
INKmune™

INKmune is a biologic delivery system that allows us to deliver the missing S1 (priming signal) to the patient’s resting NK cells.  INKmune is delivered by a simple IV infusion.  

Learn More

Products
INB03

INB03 is a checkpoint inhibitor that targets myeloid-derived suppressor cells (MDSC) in the tumor microenvironment that produce an immunosuppressive shield that prevents the patient’s immune system from attacking the cancer.

Learn More

Stay Tuned
Latest News

Corporate
Presentation
Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST